

16th World Congress on Cancers of the Skin®

12th Congress of the European Association of Dermato-Oncology

AUGUST 31 – SEPTEMBER 3, 2016

VIENNA, AUSTRIA



Friday, September 2, 2016

Time	Festsaal		Zeremoniensaal		Rittersaal		Geheime Ratstube	
8:00 AM – 8:55 AM	SY19	Controversies: Is There a Dysplastic Nevus? <i>Chairs:</i> P. Tschandl (Vienna, Austria) C. Hoeller (Vienna, Austria)	SY20	Chemotherapy of Skin Cancers - Does It Still Have a Role in Our Algorithms? <i>Chairs:</i> P. Lorigan (Manchester, UK) R. Gutzmer (Hannover, Germany)	SY21	Cutaneous Side Effects of Oncological Drugs <i>Chairs:</i> C. Lebbe (Paris, France) V. Sibaud (Toulouse, France)	FC1	Free Communications <i>Chairs:</i> P. Petzelbauer (Vienna, Austria) M. Herlyn (Philadelphia, USA)
	SY19-1 8:00 AM	Pro B. Bastian (San Francisco, USA)	SY20-1 8:00 AM	Chemotherapy for melanoma – last resort or still an option? P. Lorigan (Manchester, UK)	SY21-1 8:00 AM	Cutaneous side effects of drugs in general oncology V. Sibaud (Toulouse, France)	FC1-1 8:00 AM	The role of the lymphovasculture during skin cancer development P. Petzelbauer (Vienna, Austria)
			SY20-2 8:13 AM	Chemotherapy for metastatic SCC R. Gutzmer (Hannover, Germany)			FC1-2 8:12 AM	Wnt signalling as a metabolic regulator in melanoma cells V. Sherwood (Dundee, UK)
	SY19-2 8:20 AM	Contra H. Kittler (Vienna, Austria)	SY20-3 8:26 AM	Chemotherapy for cutaneous lymphomas L. Geskin (New York, USA)	SY21-2 8:30 AM		Cutaneous side effects of novel PI3K inhibitors in mono- and combination-therapy K. Schindler (Vienna, Austria)	FC1-3 8:24 AM
	8:40 AM	<i>Discussion with the audience</i>	SY20-4 8:39 AM	Chemotherapy in the treatment of orphan skin cancers R. Loewe (Vienna, Austria)		FC1-4 8:36 AM		Upregulated sonic hedgehog activity drives the development of congenital nevi A. Chitsazan (Herston/Brisbane, Australia)
						FC1-5 8:48 AM		Understanding benign T-cell infiltration in mycosis fungoides: Malignant clones are not alone P.A. Vieyra-Garcia (Graz/Boston, Austria, MA; USA)
9:00 AM – 10:30 AM	SY22	Neo-adjuvant Treatment in Skin Cancer Patients <i>Chairs:</i> H. Pehamberger (Vienna, Austria) H. Gogas (Athens, Greece)	SY23	Cutaneous Lymphoma II – Therapy Update <i>Chairs:</i> L. Geskin (New York, USA) L. Papadavid (Greece)	SY24	Genetics of Skin Cancer <i>Chairs:</i> I. Okamoto (Vienna, Austria) B. Bastian (San Francisco, USA)	SY25	Dermoscopy II Experts <i>Chairs:</i> TBA
	SY22-1 9:00 AM	From adjuvant to neo-adjuvant treatment in skin cancers – time to change the paradigm? J. J. Grob (Marseille, France)	SY23-1 9:00 AM	EORTC treatment guidelines 2015 F. Trautinger (St. Poelten, Austria)	SY24-1 9:00 AM	Genetics of melanocytic tumors – From benign to malignant B. Bastian (San Francisco, USA)	SY25-1 9:00 AM	Challenging cases W. Stolz (Munich, Germany)
	SY22-2 9:20 AM	Can biomarkers help us to select patients for neo-adjuvant treatment? H. Gogas (Athens, Greece)	SY23-2 9:15 AM	Use of alemtuzumab and radiation therapy in CTCL R. A. Clark (Boston, USA)	SY24-2 9:20 AM		Genetic background and UV – how do they cooperate to form skin cancer N. Hayward (Brisbane, Australia)	SY25-2 9:15 AM
	SY22-3 9:40 AM	Neoadjuvant treatment in melanoma – a useful strategy?	SY23-3 9:30 AM	Mogamolizumab in CTCL M. Duvic (Houston, USA)		SY25-3 9:30 AM		Nail cases L. Thomas (Lyon, France)
			SY23-4 9:45 AM	Treatment update on b-cell lymphomas M. Bagot (Paris, France)	SY24-3 9:40 AM	Acquired mutations in melanoma, B-raf and beyond G. McArthur (Brisbane, Australia)	SY25-4 9:45 AM	Non-pigmented cases C. Rosendahl (Brisbane, Australia)

		J. Kirkwood (Pittsburgh, USA)						
	SY22-4 10:00 AM	Surgical strategies to maximize the outcome of neo-adjuvant treatment A. Testori (Milano, Italy)	SY23-5 10:00 AM	Brentuximab vendotin in CTCL R. Stadler (Minden, Germany)	SY24-4 10:00 AM	The role of telomers in skin tumors R. Kumar (Heidelberg, Germany)	SY25-5 10:00 AM	Unusual cases H. Kittler (Vienna, Austria)
			SY23-6 10:15 AM	Photopheresis in CTCL R. Knobler (Vienna, Austria)			SY25-6 10:15 AM	Challenging high risk patients S. Puig (Barcelona, Spain)
10:30 AM – 11:00 AM	Coffee Break							
11:00 AM – 12:00 AM	PL4	Cutaneous Lymphoma, New Drugs <i>Chairs:</i> R. Knobler (Vienna, Austria) J. Kirkwood (Pittsburgh, USA)						
	PL4-1 11:00 AM	New insights in understanding T-cell biology in cutaneous lymphoma R. Clark (Boston, USA)						
	PL4-2 11:30 AM	New therapies – price vs. value – can we afford it? J. Larkin (London, UK)						
12:15 AM – 1:15 PM	Lunch Break		SAT6	Bristol-Myers Squibb Lunch Symposium <i>Chair:</i> C. Hoeller (Vienna, Austria)				
			12:15 PM	Welcome and introduction				
			SAT6-1 12:20 PM	Melanoma 2016: recent data and clinical implications J. Weber, (New York, USA)				
			SAT6-2 12:30 PM	The principles and practice of immuno-oncology adverse event management J. Larkin (London, UK)				
			SAT6-3 12:40 PM	Expert insights into patient management – Melanoma case presentations by C. Lebbé and an interactive discussion moderated by C. Hoeller C. Lebbe (Paris, France) Host: C. Hoeller (Vienna, Austria)				
			13:10 PM	Summary and close C. Hoeller (Vienna, Austria)				
1:30 PM – 2:50 PM	SY26	How to Overcome Drug Resistance <i>Chairs:</i> C. Blank (Amsterdam, Netherlands) P. Ascierto (Napels, Italy)	SY27	Systemic Treatment of Non-Melanoma Skin Cancer <i>Chairs:</i> A. Stratigos (Athens, Greece) M. Bylaite (Vilnius, Lithuania)	SY28	Tumor Immunology <i>Chairs:</i> T. Tüting (Bonn, Germany) G. Stingl (Vienna, Austria)	SY29	What's a Drugs Value? <i>Chairs:</i> H. Pehamberger (Vienna, Austria) M. Binder (Vienna, Austria)
	SY26-1 1:30 PM	Update on resistance mechanisms against targeted drugs TBA	SY27-1 1:30 PM	Systemic drugs to prevent non-melanoma skin cancer A. Stratigos (Athens, Greece)	SY28-1 1:30 PM	How tumors escape immune surveillance T. Tüting (Bonn, Austria)	SY29-1 1:30 PM	How do we define value in cancer care J. Kirkwood (Pittsburgh, USA)
	SY26-2 1:50 PM	The role of epigenetic adaptations in the escape from BRAF inhibitor therapy K. Smalley (Tampa, USA)	SY27-2 1:50 PM	Systemic treatment of bcc – current status and future directions R. Kunstfeld (Vienna, Austria)	SY28-2 1:50 PM	Killing or control – what defines an effective tumor immune-response? W. Weninger (Sidney, Australia)	SY29-2 1:45 PM	The cost impact of modern skin cancer treatments – the European view M. Binder (Vienna, Austria)
	SY26-3		SY27-3	Systemic treatment of metastatic SCC – what's new?	SY28-3	The role of dendritic cells in tumor immunology	SY29-3	The cost impact of modern skin cancer treatments – the US view

	2:10 PM	Resistance against checkpoint inhibitors – what are the mechanisms? P. Ascierto (Napels, Italy)	2:10 PM	J. Hofbauer (Zuerich, Switzerland)	2:10 PM	G. Stingl (Vienna, Austria)	2:10 PM	S. Agarwala (New York, USA)
	SY26-4 2:30 PM	Strategies to overcome drug resistance in melanoma C. Blank (Amsterdam, Netherlands)	SY27-4 2:30 PM	Systemic treatment of cutaneous sarcomas R. Gutzmer (Hanover, Germany)	SY28-4 2:30 PM	Inhibition of the novel immune checkpoint CEACAM1 to enhance anti-tumor immunological activity G. Markel (Tel Aviv, Israel)	SY29-4 2:15 PM	Solutions in the adaption to new cancer treatment paradigms C. Zielinski (Vienna, Austria)
3:00 PM – 4:00 PM	Coffee Break		SAT7	MSD Vienna Coffeehouse Symposium Great Debates of Immuno-Oncology Therapies in Advanced Melanoma <i>Chair: A. Hauschild (Kiel, Germany)</i>				
			3:00 PM	Welcome and introduction A. Hauschild (Kiel, Germany)				
			SAT7-1 3:05 PM	Clinical data update on immune checkpoint inhibitors A. Hauschild (Kiel, Germany)				
			SAT7-2 3:15 PM	Debate-I Combination immunotherapy vs single-agent immunotherapy: does combination immunotherapy outweigh monotherapy in 1L settings? S. Agarwala (New York, USA)				
			SAT7-3 3:25 PM	Debate-II Targeted therapy vs immunotherapy: is targeted therapy the most appropriate 1L treatment choice for BRAF-mutated patients? C. Blank (Amsterdam, Netherlands)				
			SAT7-4 3:35 PM	Debate-III Novel combinations: should the novel immunotherapy combination regimens be built on the 1L clinical profile established by the ipilimumab + nivolumab combination? J. Weber (New York, USA)				
			3:45 PM	Q&A Session and Close				
4:05 PM – 5:25 PM	SY30	UV-Protection, Vitamin D and Photoaging <i>Chairs: H. Höngismann (Vienna, Austria) H. Lim (Detroit, USA)</i>	SY31	Melanoma Surgery: Lymph Nodes to Distant <i>Chairs: M. Ross (Houston, USA) R. Andtbacka (Salt Lake City, USA)</i>	SY32	Smart Sequencing or Combination Therapy – in Search for the Best Strategy <i>Chairs: N. Haass (Queensland, Australia) K. Smalley (Tampa, USA)</i>	SY33	Orphan Skin Cancer - Epidemiology, Histopathology, Biology, Therapy <i>Chairs: R. Loewe (Vienna, Austria) P. Saiag (Paris, France)</i>
	SY30-1 4:05 PM	UV – the good and the bad sides S. Beissert (Leipzig, Germany)	SY31-1 4:05 PM	Lymph node surgery in melanoma patients J. Gershenwald (Houston, USA)	SY32-1 4:05 PM	Sequencing in melanoma – which options do we have? C. Blank (Amsterdam, Netherlands)	SY33-1 4:05 PM	What is “orphan skin cancer” R. Loewe (Vienna, Austria)
	SY30-2 4:27 PM	Sun protection – how does it work and does it work? H. Höngismann (Vienna, Austria)	SY31-2 4:25 PM	Surgery of distant metastases – when and how A. Testori (Milan, Italy)	SY32-2 4:25 PM	How can we make the best use of kinase inhibitors in melanoma? A. Hauschild (Kiel, Germany)	SY33-2 4:20 PM	Orphan drugs for orphan skin cancer J. Becker (Essen, Germany)

	SY30-3 4:49 PM	Vitamin-D – what you always wanted to know (basis for normal values, sources, physiological role, pathologies of deficiency) H. Lim (Detroit, USA)	SY31-3 4:45 PM	Cutaneous metastases – when to excise and when to treat R. Andtbacka (Salt Lake City, USA)	SY32-3 4:45 PM	How can we make the best use of immunotherapy in melanoma? P. Ascierto (Napels, Italy)	SY33-3 4:40 PM	Surgical therapy of cutaneous sarcomas P. Funovics (Vienna, Austria)
	SY30-4 5:11 PM	Laser therapy of photoaging D. Sarnoff (New York, USA)	SY31-4 5:05 PM	How does the role of surgery in melanoma change in the current therapeutic landscape M. Ross (Houston, USA)	SY32-4 5:05 PM	How can we combine new drugs with local treatment strategies R. Dummer (Zuerich, Switzerland)	SY33-4 5:00 PM	Dermatofibrosarcoma protuberans – current guidelines P. Saiag (Paris, France)
							SY33-5 5:15 PM	Genomic and immune heterogeneity in non-viral merkel cell carcinoma R. Tothill (Melbourne, Australia)
5:30 PM – 6:30 PM	SY34	Controversies: Sentinel Node and Completion Lymph Node Dissection – Standard of Care? <i>Chairs:</i> H. Pehamberger (Vienna, Austria) J. Gershenwald (Houston, USA)	SY35	Skin Cancer in Special Patient Subgroups <i>Chairs:</i> A. Geusau (Vienna, Austria) J. Olah (Szeged, Hungary)	SY36	Locoregional Therapy of Melanoma Metastases <i>Chairs:</i> L. Kandolf-Sekulovic (Belgrade, Serbia) S. Agarwala (Bethlehem, USA)	SY37	Psychodermatooncology <i>Chairs:</i> E. Lehner-Baumgartner (Vienna, Austria)
	SY34-1 5:30 PM	Pro M. Ross (Houston, USA)	SY35-1 5:30 PM	Epidemiology and prevention of skin cancer in immunosuppressed patients A. Geusau (Vienna, Austria)	SY36-1 5:30 PM	Therapies for patients with locoregional metastases – what are our current options? R. Dummer (Zuerich, Switzerland)	SY37-1 5:30 PM	Breaking bad news to cancer patients – the do’s and the don’t’s TBA
	SY34-2 6:00 PM	Contra C. Garbe (Tuebingen, Germany)	SY35-2 5:50 PM	Treatment of skin cancer in immunosuppressed patients – different from immunocompetent patients? C. Lebbe (Paris, France)	SY36-2 5:50 PM	Intralesional therapies – what’s around the corner? S. Agarwala (Bethlehem, USA)	SY37-2 6:00 PM	Strategies to support our patients beyond pharmacotherapy – what everyone can do E. Lehner- Baumgartner (Vienna, Austria)
		<i>Discussion with the audience</i>	SY35-3 6:10 PM	Skin cancer in patients previously irradiated – a frequent event? A. Geller (Boston, USA)	SY36-3 6:10 PM	Intralesional and systemic therapies – which combinations are most promising? R. Andtbacka (Salt Lake City, USA)		
8:00 PM	OT3	Networking Evening Heuriger Welser						